Compare STIM & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STIM | GDL |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5M | 94.9M |
| IPO Year | 2018 | N/A |
| Metric | STIM | GDL |
|---|---|---|
| Price | $2.09 | $8.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 11.2K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $129,873,000.00 | N/A |
| Revenue This Year | $101.67 | N/A |
| Revenue Next Year | $10.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.61 | N/A |
| 52 Week Low | $1.25 | $7.65 |
| 52 Week High | $5.92 | $8.13 |
| Indicator | STIM | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 68.69 | 48.25 |
| Support Level | $1.34 | $8.35 |
| Resistance Level | $1.50 | $8.47 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 94.80 | 52.66 |
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.